Harpoon Therapeutics Inc., a portfolio company of Arix Bioscience PLC (LON:ARIX) is planning to float in the US.
Arix said Harpoon has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering.
READ: Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy
Harpoon is a clinical-stage immuno-oncology company developing T cells to fight cancer and other diseases.